Tagged with Clinical Trials,

Hungary Dr. György Blaskó, former President and Chairman of the Hungarian European Clinical Research Infrastructure Network, explains the role of the research network, the impact it has on the Hungarian clinical research environment, and the areas of improvement moving forward.   Domestic centralized health care and the presence of a single…

Thailand PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now.   Thailand is in the midst of an economic transformation with healthcare at its heart. With four years of around three-four percent annual GDP growth behind it, ASEAN’s second-largest economy has implemented an ‘Industry 4.0’ policy through which…

Pharma Market Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech Republic is in second place, followed by Romania and Hungary Made with Visme Infographic Maker     The CEE countries that exported…

Clinical Trials Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in the country since 2015 has some stakeholders concerned about the future of Hungary as a regional clinical trials hub.   …

Puerto Rico Merck (MSD outside of the USA) is celebrating its 70-year anniversary in Puerto Rico this year. Executive Managing Director Wendy Perry highlights the company’s extensive footprint on the island which includes commercial, manufacturing and clinical research operations. She stresses the importance of maintaining a strong commercial presence locally to address…

Thailand As Thailand’s focus has shifted towards R&D over the past few years, the number of in-country clinical trials being conducted has increased concurrently. From 2011 to 2016, Thailand conducted a total of 739 clinical trials, the largest number within the Southeast Asian region, followed by Singapore (610 trials) and Malaysia…

Puerto Rico Puerto Rico has long been known for its pharma manufacturing prowess, but multinational companies are increasingly looking to conduct clinical trials there, thanks to strong institutional support, a strong example set by R&D-focused university spin-off companies, and the island’s unique ethnic profile.   The Hispanic population has been historically underrepresented…

Thailand Thailand is becoming an increasingly attractive location for pharma companies to conduct clinical trials, with multinationals such as Novo Nordisk and Boehringer Ingelheim conducting more and more of their global trials in the country.   We are very active in engaging Thai doctors and patients in benefiting from involvement in…

Puerto Rico José F Rodríguez Orengo is the CEO and Chief Scientific Officer at the Fundación de Investigación (FDI) Clinical Trials, Puerto Rico’s main clinical research centre. In this interview, Rodríguez Orengo highlights his priorities of extending the capabilities and also becoming active in the space of public health. He also discusses…

Spain Through a merger between INC Research and inVentiv Health in 2018, Syneos Health has become the industry’s only fully integrated biopharmaceutical solutions organisation which includes one of the world’s top three global clinical research organisations (CRO) and a contract commercial organisation (CCO). Rosa Gonzalez Galindo explains the scale and scope…

Taiwan Professor Ming-Shiang Wu, director of the Taiwan Clinical Trial Consortium, elaborates on the activities of the organization and its role to promote Taiwan’s clinical trial infrastructure and attract more international trials to the country. He also goes on to explain the key strengths of Taiwan within the Asia Pacific region.…

Egypt Basyouni Abuseif, country president and CPO Head at Novartis Egypt, explains how the Swiss company has taken over the leadership position in the Egyptian pharmaceutical market despite economic and political challenges. He also highlights recent achievements of the government in fighting Hepatitis C, while emphasizing the need for more attention…